Anti-angiogenic treatment like bevacizumab has showed effect on HB, so we hypothesized that anlotinib could trigger HB regression <i>via</i> its inhibitory effect on VEGF.<h4>Case presentation</h4>We will share our experience in treating a 62-year-old woman with multiple recurrent lumbar and sacral cord HBs. This evidence concerns the gene VEGFA and hemoglobin measurement.